Denmark-based Abacus Medicine A/S announced on 29 May that it was postponing an initial public offering planned for the Frankfurt Stock Exchange because of unfavourable market conditions. The parallel trade company was reportedly planning to raise €50 million to finance expansion.
The company’s biggest market is Germany where it sells drugs purchased at cheaper prices in other European markets.